NanoString Q2 Revenues Up 73 Percent | GenomeWeb

NEW YORK (GenomeWeb) - NanoString Technologies reported after the close of the market Wednesday that its second quarter revenues increased 73 percent, attributable to collaboration revenue, instrument sales, and consumables pull-through.

For the three months ended June 30, the Seattle-based molecular diagnostics firm reported total revenues of $22.6 million compared to $13.1 million in the prior-year period, beating the average Wall Street analyst estimate of $19.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Sponsored by

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Sponsored by

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Sponsored by

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Sponsored by
Twist BioScience

This webinar will cover methodologies for genome-wide screening with CRISPR/Cas9 in human pluripotent stem cells (hPSCs).